Best Peptides for Weight Loss Research (2026): The GLP-1 Compounds Labs Actually Study

Quick answer: the weight-loss research conversation is dominated by engineered incretin peptides - the triple agonist retatrutide, the dual agonist tirzepatide, the GLP-1 agonist semaglutide, and the amylin analogue cagrilintide - plus two mechanistically different veterans, the GHRH analogue tesamorelin and the HGH fragment AOD-9604. Some are approved medicines; some are still investigational; one largely failed its human trials. All are supplied by New-U as research-use-only material, not for human use .

How to read this list. "Best" here means most-studied and most-discussed in weight-loss research - not a recommendation, a dose, or a promise of results. We describe each compound's mechanism, the headline trial number where one exists, and exactly where the evidence stops. There are no protocols on this page, and none of this is medical advice.

Ask "what are the best peptides for weight loss?" and you are really asking about the incretin revolution. The drugs behind the headlines - Ozempic, Wegovy, Mounjaro, Zepbound - are engineered peptides, which is why weight-loss research and peptide research have converged so completely. Below, the compounds are grouped by mechanism, ranked loosely by how far the evidence has travelled, and kept honest about the gap between an eye-catching trial number and an approved product.

Group 1: The Incretin Agonists (the GLP-1 family)

These mimic the gut hormones the body releases after eating. They slow gastric emptying, dampen appetite signalling and improve glucose handling. The class splits by how many receptors each engages - and, broadly, engaging more receptors has tracked with larger reported effects.

1. Retatrutide - the triple agonist

Retatrutide (Eli Lilly's LY3437943, sometimes nicknamed "GLP-3" in search) hits three receptors at once - GLP-1, GIP and glucagon. The glucagon arm is the twist: it is studied for a direct effect on energy expenditure on top of the appetite suppression the other two provide. In phase-2 obesity research it reported the largest mean weight reductions of the whole class . The caveat is decisive: retatrutide is still investigational and not approved anywhere , with pivotal trials ongoing. The biggest number in the class also has the least regulatory finality. See the full retatrutide research guide.

2. Tirzepatide - the dual agonist

Tirzepatide engages GIP and GLP-1 and is the most potent approved option, marketed as Mounjaro (diabetes) and Zepbound (obesity). Its pivotal obesity programme reported mean reductions well beyond semaglutide's. It is the compound that proved "more than one receptor" was not just theory. Our tirzepatide vs semaglutide comparison unpacks the head-to-head.

3. Semaglutide - the GLP-1 benchmark

Semaglutide - Ozempic and Wegovy - is the single-receptor GLP-1 agonist that started the modern wave and remains the reference every newer compound is measured against. It answers the most-asked question in the category directly: yes, Ozempic is a peptide. Fully approved, the most real-world data, and the mechanistic baseline for the group.

4. Cagrilintide - the amylin angle

Cagrilintide is a long-acting amylin analogue - a different satiety hormone entirely - which is why it is studied alongside a GLP-1 rather than against it. The CagriSema combination (cagrilintide + semaglutide) is one of the most-watched pairings in the pipeline. Investigational, but a genuinely distinct mechanism. Read the CagriSema & cagrilintide guide.

Group 2: The Mechanistically Different Veterans

Not everything in the weight-loss research map is an incretin. These two predate the GLP-1 wave and work through completely different pathways - and they are an honesty check on the category.

5. Tesamorelin - the GH-axis / visceral-fat compound

Tesamorelin is a stabilised GHRH analogue that raises the body's own growth-hormone axis, and it carries dedicated research on visceral adipose tissue specifically. It is FDA-approved, but only for HIV-associated lipodystrophy - not general weight loss. It belongs on the map because visceral fat is a distinct research target, but it is not an appetite drug and should not be filed next to the incretins. See the tesamorelin guide.

6. AOD-9604 - the lipolysis fragment

AOD-9604 is a fragment of growth hormone (residues 176-191) studied for lipolysis without GH's blood-sugar effects. It is the category's cautionary tale: despite an appealing mechanism, its human weight-loss trials largely failed to beat placebo . We include it precisely because an honest "best of" has to show where a good-sounding mechanism did not translate.

The At-a-Glance Table

Mechanism is not outcome, and a trial number is not a product. The biggest reported reductions in this list belong to a compound (retatrutide) that is not approved anywhere , while the compound with a promising fat-loss mechanism (AOD-9604) largely failed its human trials . New-U supplies these as research-use-only reagents for laboratory work, not for human use . Nothing here is dosing guidance, a weight-loss protocol, or medical advice - the licensed medicines (Wegovy, Zepbound, Ozempic, Mounjaro) are a separate category from the research-grade compounds sold here.

"Natural Ozempic" and OTC alternatives - a quick myth-check

Searches for "natural Ozempic" and over-the-counter GLP-1 boosters are everywhere. The honest research position: foods and fibres that nudge your own GLP-1 release do so at a tiny fraction of the pharmacological effect of an engineered agonist, and no supplement replicates a receptor agonist. The compounds above are studied precisely because they are engineered peptides, not because a capsule can stand in for one. For the wider pipeline beyond today's leaders, see beyond GLP-1: the next obesity-research wave and the GLP-1 research-compound comparison.

Sourcing, purity and handling

Because these are the most-counterfeited compounds in the research space, purity documentation matters more here than anywhere. Every research question in this category depends on the vial actually containing what the label says - so read the Certificate of Analysis guide before anything else. The peptide compounds ship as lyophilised powder; see the reconstitution guide and the bacteriostatic-water guide for laboratory handling.

Frequently Asked Questions

Is Ozempic a peptide? Yes - Ozempic is semaglutide, a 31-amino-acid GLP-1 receptor agonist peptide engineered for a long half-life. Tirzepatide and retatrutide are peptides too, which is why the leading weight-loss drugs and peptide research are effectively the same conversation.

Which is the "strongest" weight-loss peptide? In reported phase-2 trial data, the triple agonist retatrutide showed the largest mean reductions, ahead of tirzepatide and then semaglutide. But retatrutide is investigational and unapproved - a bigger number is not a finished, licensed product, and this is not a recommendation.

Are any of these FDA-approved? Semaglutide (Wegovy) and tirzepatide (Zepbound) are approved for weight management. Tesamorelin is approved only for HIV-associated visceral fat. Retatrutide, cagrilintide and AOD-9604 are investigational. The research-grade material New-U supplies is unapproved laboratory reagent - not the licensed drug.

Do these need bacteriostatic water? The peptide compounds ship as lyophilised powder and are reconstituted with bacteriostatic water for laboratory handling. See our bacteriostatic-water guide and reconstitution guide.

Related Reading

From the Lab - Peptides on LinkedIn & Facebook

The GLP-1 & Metabolic Research Catalog, Lab-Verified.

Retatrutide, tirzepatide, semaglutide, cagrilintide, tesamorelin and AOD-9604 - sealed 10-vial packs, >99% HPLC purity with a per-batch Certificate of Analysis. Research use only - not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

© 2026 New-U Research Compounds · new-u.io · @new.u.io